经济观察网 近期药捷安康-B（02617.HK）股价呈现波动下行态势。根据内部数据库，在近一周有交易 的日子中，2月16日收盘价为67.80港元，单日跌幅1.38%；2月20日收盘价为66.60港元，单日跌幅 1.77%。从2月16日至20日，区间跌幅为3.13%，振幅达7.13%，成交相对清淡，换手率较低。资金流向 方面，2月20日总净流入492.68万元，但主力资金净流入为0，散户资金活跃。同期，所属生物技术板块 上涨1.64%，但个股表现与板块走势分化。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Insights - The article highlights the top short-selling stocks in the market, with BYD Company Limited (81211) leading with a short-selling ratio of 100.00% [1][2]. Group 1: Short-Selling Ratios - BYD Company Limited (81211) has a short-selling ratio of 100.00% [2][3]. - JD.com (89618) follows with a short-selling ratio of 97.67% [2][3]. - Kuaishou Technology (81024) has a short-selling ratio of 80.79% [2][3]. Group 2: Short-Selling Amounts - Meituan (03690) has the highest short-selling amount at 2.11 billion [2]. - Alibaba Group (09988) follows with a short-selling amount of 1.673 billion [2]. - Xiaomi Corporation (01810) has a short-selling amount of 1.482 billion [2]. Group 3: Deviation Values - BYD Company Limited (81211) has the highest deviation value at 44.67% [3]. - Jinfang Pharmaceutical (02595) has a deviation value of 35.39% [3]. - Kuaishou Technology (81024) has a deviation value of 34.76% [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥捷安康 (南京 )科技股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02617 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,666,673 | RMB | | 1 RMB | | 301,666,673 | | 增加 / 減少 (-) | | | 2,100,000 | | | RMB | | 2,100,000 | | 本月底結存 | | | 303,766,673 | RMB | | 1 RMB | | 303,766,673 | 足夠公眾持股量的確認 ...

Group 1 - The company announced the completion of a placement agreement on January 20, 2026, successfully placing a total of 2.1 million shares at a price of HKD 92.85 per share to at least six subscribers [1] - The 2.1 million shares represent approximately 0.70% of the existing issued H shares and about 0.53% of the total issued shares of the company, with the post-placement issued H shares increasing to about 0.69% [1] - The total proceeds from the placement amount to approximately HKD 195 million, with a net amount of about HKD 190 million after deducting placement commissions and related costs, resulting in a net issue price of approximately HKD 90.54 per share [1] Group 2 - The company plans to allocate approximately 60% of the net proceeds, or about HKD 114 million, to fund clinical trials for its core product Tinengotinib in the treatment of cholangiocarcinoma (CCA) and other indications [2] - About 30% of the net proceeds, or approximately HKD 57.04 million, will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [2] - Approximately 10% of the net proceeds, or about HKD 19.01 million, will be allocated for working capital and general corporate purposes [2]

Group 1 - The company completed a placement agreement on January 20, 2026, successfully placing a total of 2.1 million shares at a price of HKD 92.85 per share to at least six subscribers [1] - The 2.1 million shares represent approximately 0.70% of the existing issued H shares and about 0.53% of the total issued shares prior to the placement [1] - The total proceeds from the placement amount to approximately HKD 195 million, with a net amount of about HKD 190 million after deducting commissions and related costs, resulting in a net issue price of approximately HKD 90.54 per share [1] Group 2 - The net proceeds from the placement will be allocated as follows: approximately 60% or HKD 114 million for funding clinical trials of the core product Tinengotinib for cholangiocarcinoma (CCA) and other indications [2] - About 30% or HKD 57.04 million will be used for the development of other products, including TT-00973, TT-01488, and other molecules [2] - Approximately 10% or HKD 19.01 million will be allocated for working capital and general corporate purposes [2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； FF305 公司名稱： 藥捷安康(南京)科技股份有限公司 呈交日期： 2026年1月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 茲提述藥捷安康（南京）科技股份有限公司（「本公司」）日期為2026年1月14日的公 告（「該公告」），內容有關配售事項。除文義另有所指外，本公告所用詞彙與該公 告所界定者具有相同涵義。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售任何證券的要約或招攬購買或認購任何證券的任何要約。除非已根據1933年美國證券法（經 修訂）登記或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開 發售將僅以招股章程的方式進行，有關招股章程可向證券發行人或賣方取得，並載有發行人及 其管理層的詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 TransThera Sciences (Nan ...

Group 1 - Hong Kong's Hang Seng Index fell by 0.04%, down 11 points, closing at 26,552 points, while the Hang Seng Tech Index decreased by 0.66% with a trading volume of HKD 129.8 billion in the morning session [1] - Pop Mart (09992) surged over 8% as the company repurchased shares worth HKD 251 million [1] - Major airlines continued to rise, with strong expectations for industry growth; China Southern Airlines (01055) increased by 3.72%, China Eastern Airlines (00670) by 4.56%, and Air China (00753) by 2.5% [1] Group 2 - Weisheng Holdings (03393) rose nearly 9%, reaching new highs as the State Grid increased its investment scale, indicating a favorable phase for smart meter investments [2] - Health Road (02587) increased by over 4% after the controlling shareholder extended the lock-up period, and the company repurchased 327,000 shares recently [3] - Blucube (00325) rose against the trend by 3.95%, benefiting from the expansion of China's trendy toy industry and the enrichment of its IP system and product matrix [4] Group 3 - Hou Shang Ayi (02589) saw a rise of over 10% as its 25-year performance forecast exceeded expectations, with net profit expected to grow by up to 60% year-on-year [5] - Gigadevice (03986) increased by over 5%, reaching a new high as Micron reported worsening shortages of memory chips, indicating that supply tightness will persist beyond this year [6] - Damai Entertainment (01060) rose over 4% after announcing its entry into the museum sector, positioning itself to benefit from the upgrading of consumer structures [7] Group 4 - The commercial aerospace sector experienced declines, with Asia Pacific Satellite (01045) dropping by 6.9% and Goldwind Technology (02208) falling by over 3% [8] - Jiayuan Ankang-B (02617) fell over 9% as it proposed a placement to raise HKD 190 million, primarily for core product development [9]

Group 1 - The insurance sector saw significant gains, with China Life (02628) up 3.81%, China Pacific Insurance (02601) up 2.31%, and Ping An (02318) up 1.17%. Notably, major insurance companies reported a doubling in premium income through bancassurance channels as of January 8, 2026 [1] - The commercial aerospace sector experienced a notable decline, with companies like JunDa Co. (02865) down 7.19% and Asia Pacific Satellite (01045) down 5.94%. This follows a period of intense adjustments and risk warnings from several listed companies in the sector [1] - The real estate sector showed active performance, with companies like R&F Properties (02777) up 4% and Greentown China (03900) up 5.79%. Data from the National Bureau of Statistics indicated a 0.3% month-on-month decline in new residential sales prices in first-tier cities for December 2025, a slight improvement from the previous month [2] Group 2 - HuShang Ayi (02589) reported an expected net profit of 495 million to 525 million RMB for 2025, reflecting a year-on-year growth of 50% to 60% [3] - Yi Communications Group (08031) saw a surge of over 70% upon resuming trading, with a current increase of 53.85%. The company announced a share acquisition deal involving 210 million shares at a price of 0.276 HKD per share, which is a 15.08% discount from the pre-suspension closing price [3] - Guorui Life (00108) experienced an increase of over 11% after announcing a deal to acquire 78.29% of Chunyu Doctor for 269 million RMB, marking its entry into the digital healthcare sector [4]

Group 1 - The stock of药捷安康-B (02617.HK) experienced a significant decline, dropping over 10% at one point and currently down 9.02% to 84.7 HKD [1] - The trading volume reached 117 million HKD, indicating active market participation despite the decline [1]